Free preview
MD Pharmacology NMC syllabus ~5 min read Recent advances last updated on 2026-06-19

Adrenergic Drugs

Sympathomimetics & Adrenergic Antagonists — Receptors, Agents, Shock Therapy & Recent Advances

Past RGUHS + DNB + MPMSU + MUHS + VNSGU · 27 RGUHSMar '26 RGUHSSep '25 MPMSUJan '25 VNSGUJan '25 VNSGUSep '25 VNSGUJun '23 RGUHSNov '22 RGUHSMay '22 DNBJun '22 VNSGUApr '22 RGUHSNov '21 RGUHSJul '21 RGUHSJun '20 MUHSWinter '20 MPMSU2018 MPMSUMay '18 MPMSU2018 MUHSWinter '18 MUHSWinter '18 MPMSU2016 VNSGUApr '16 DNBDec '13 DNBDec '12 DNBDec '11 RGUHSMay '10 RGUHSSep '07 MPMSU2006

Introduction & terminology

  • Adrenergic (sympathomimetic) drugs — mimic the actions of adrenaline or of sympathetic stimulation; antiadrenergic / adrenergic antagonist drugs block the receptor actions of catecholamines at α, β or both adrenoceptor classes.
  • Three endogenous catecholamines — noradrenaline (NA) — transmitter at most postganglionic sympathetic terminals; adrenaline (Adr) — the adrenal-medullary hormone acting via its circulating concentration; dopamine (DA) — central transmitter (basal ganglia, CTZ) with a limited renal-vascular peripheral role.
  • Isoprenaline — synthetic pure β agonist with negligible α action — the pharmacological tool used to define β responses; NA and Adr underpin the "fight-or-flight" response.
  • Scope — drugs either mimic catecholamines, block their synthesis / release / reuptake, or antagonise them at adrenoceptors — the framework for this whole topic.
Continue reading

Adrenergic Drugs

PharmaNotes Pro · LAQ

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.